The argument arrives at a moment when Parkinson’s research is confronting a difficult reality: therapies that improve symptoms have transformed clinical care, but treatments that reliably slow or stop neurodegeneration remain elusive. Levodopa and related dopaminergic drugs can restore signaling in damaged motor circuits, yet they do not remove the underlying causes of neuronal injury. Experimental approaches aimed at alpha-synuclein have generated intense interest, including antibodies, vaccines, aggregation inhibitors and gene-based technologies. However, the authors’ central premise is that alpha-synuclein may be only one component of a complex biological network. If inflammation, mitochondrial dysfunction, impaired protein clearance, vascular changes or other misfolded proteins are simultaneously damaging the brain, attacking alpha-synuclein alone may leave major drivers of disease untouched.

Alpha-synuclein is a neuronal protein involved in synaptic function, but under pathological conditions it can misfold, aggregate and spread through interconnected regions of the nervous system. These abnormal assemblies are associated with Lewy bodies and Lewy neurites, microscopic structures found in Parkinson’s disease and related disorders. Yet the presence of alpha-synuclein does not fully explain clinical diversity. Some people develop predominantly tremor-related disease, while others experience early gait impairment, cognitive decline, sleep disturbance, autonomic dysfunction or psychiatric symptoms. The timing and severity of these features can differ widely, suggesting that additional biological processes influence which neural systems become vulnerable and how quickly damage progresses.

Inflammation is one of the most important candidates in this wider model. The brain’s resident immune cells, known as microglia, constantly survey neural tissue and respond to injury or abnormal proteins. In a healthy state, this response can help remove debris and restore balance. When activation becomes persistent, however, microglia may release inflammatory mediators, reactive oxygen species and other signals capable of injuring neurons. Astrocytes, which support neurons and regulate the chemical environment of the brain, can also shift into reactive states that alter metabolism, synaptic signaling and immune communication. Rather than viewing inflammation as a secondary consequence of neuronal death, the paper emphasizes the possibility that it can become an active amplifier of degeneration.

The biological connection between alpha-synuclein and inflammation is particularly important. Misfolded alpha-synuclein can stimulate innate immune receptors on microglia and other cells, while inflammatory conditions may make neurons more vulnerable to the protein’s toxic effects. This creates a feedback loop: abnormal protein accumulation activates immune pathways, inflammation increases cellular stress, and stressed neurons become less capable of maintaining protein quality control and energy production. Mitochondria, the organelles that generate most of a cell’s energy, are especially sensitive to this combination of stressors. Damage to mitochondrial function can increase oxidative stress, impair axonal transport and weaken the neuron’s ability to survive. A therapy that suppresses one component of this cycle may therefore produce limited benefits if the rest of the network remains active.

The concept of co-pathology expands the problem beyond alpha-synuclein. Many people with Parkinson’s disease show biological evidence of additional abnormalities, including amyloid-beta plaques, tau-related changes, vascular injury or alterations associated with the immune system and lysosomal function. These features do not occur in every patient, and their effects can depend on age, genetics, disease stage and the regions of the brain involved. A person whose cognitive symptoms are influenced by amyloid or tau pathology may respond differently from someone whose disease is dominated by motor-circuit degeneration and inflammation. The authors’ framework therefore supports more precise biological classification, rather than treating Parkinson’s disease as a single uniform condition.

Such precision would require a new generation of biomarkers capable of measuring several disease mechanisms at once. Researchers are already investigating cerebrospinal-fluid assays, blood-based markers, neuroimaging techniques, genetic profiles and digital measurements derived from movement, speech and sleep. Biomarkers of alpha-synuclein aggregation could potentially be combined with indicators of immune activation, neuronal injury, lysosomal dysfunction or vascular damage. Advanced imaging may help reveal changes in dopamine terminals, microglial activity and brain connectivity, while wearable devices can track subtle fluctuations in gait and motor performance over time. The goal would be to identify biologically meaningful subtypes and match each patient with a treatment combination designed for the mechanisms most active in that individual.

This strategy could involve combining disease-modifying therapies rather than searching for a single universal drug. One treatment might reduce alpha-synuclein production or aggregation, another could restrain damaging inflammatory signaling, and a third might improve lysosomal or mitochondrial function. In patients with prominent co-pathologies, therapies directed at amyloid, tau or vascular risk might become relevant as well. Such combinations would be scientifically and clinically challenging. The treatments could interact in unexpected ways, immune suppression could create safety risks, and trials would need to determine whether a biological change actually translates into slower disability. Nevertheless, the paper’s message is that the complexity of Parkinson’s disease should be reflected in the design of therapies and clinical studies.

The authors’ proposal also challenges how success is measured. Conventional Parkinson’s trials often focus on motor scales, medication requirements or short-term changes in symptoms. Those outcomes remain essential, but they may not capture whether a treatment is altering the underlying disease process. A therapy that reduces inflammation might not immediately improve tremor, while a treatment that targets co-pathology could first influence cognition, sleep or autonomic function. Future trials may need longer follow-up periods, molecular biomarker panels and outcome measures tailored to distinct disease subtypes. Adaptive trial designs could allow investigators to test several mechanisms simultaneously and modify treatment assignments as biological data accumulate.

The broader significance of the perspective is its rejection of a one-size-fits-all explanation for Parkinson’s disease. Alpha-synuclein remains a central target, but Webster and Harms argue that it should be studied within the larger ecosystem of immune responses, cellular stress, aging, genetics and coexisting neuropathologies. This does not guarantee that combination therapies will succeed, nor does it diminish the value of research focused on alpha-synuclein. Instead, it reframes the question: the most effective future treatment may not be the drug that neutralizes one pathological hallmark, but a carefully matched intervention that interrupts several reinforcing processes before neuronal damage becomes irreversible. For patients and researchers, that shift could mark a move from treating Parkinson’s as a single molecular disease toward treating it as a biologically diverse collection of interacting disorders.

Subject of Research: Parkinson’s disease, neuroinflammation, alpha-synuclein pathology and co-pathologies

Article Title: Rethinking single-pathology therapies by targeting inflammation and co-pathologies in Parkinson’s disease

Article References: Webster, J.M., Harms, A.S. “Rethinking single-pathology therapies by targeting inflammation and co-pathologies in Parkinson’s disease.” npj Parkinson’s Disease (2026). https://doi.org/10.1038/s41531-026-01502-9

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01502-9

Keywords: Parkinson’s disease, neuroinflammation, alpha-synuclein, co-pathology, microglia, astrocytes, neurodegeneration, precision medicine, disease-modifying therapy, biomarkers

Parkinson’s disease has traditionally been characterized by a constellation of motor symptoms—tremors, rigidity, bradykinesia, and postural instability—that appear deceptively consistent across patients. However, Bowen’s detailed analysis reveals that beneath the surface, the pathophysiological mechanisms driving these symptoms diverge markedly from one individual to another. This heterogeneity is not merely clinical but extends deep into molecular, genetic, and environmental domains, indicating that PD might actually be a spectrum of disorders with overlapping phenotypes rather than a singular disease entity.

One of the crucial insights offered is the profound variability in the underlying neurodegenerative processes. While alpha-synuclein aggregation has long been implicated as a hallmark of PD pathology, the degree, timing, and even the specific neuronal populations affected vary considerably between patients. Further complicating this picture are genetic mutations that predispose certain individuals to atypical forms of PD or related synucleinopathies, thereby influencing disease progression, symptomatology, and response to treatment. Such findings underscore the inadequacy of “one-size-fits-all” models in both clinical and research settings.

Bowen meticulously dissects the ramifications of this complexity, arguing that therapeutic interventions tailored to the dominant pathological and molecular signatures of individual patients could revolutionize PD management. Precision medicine approaches, currently transforming cancer and rare disease treatment, are posited as the future of Parkinson’s care. Potential strategies could include stratifying patients based on their genetic profiles, biomarkers, and environmental exposures to optimize drug efficacy and minimize adverse effects, heralding a new era of personalized neurology.

The implications extend beyond treatment to diagnosis as well. Traditional clinical criteria, while effective for identifying motor symptoms, fail to capture the nuanced variations in non-motor symptoms such as cognitive impairment, mood disorders, and autonomic dysfunction—all of which manifest with differing intensities and timelines. Such diversity in clinical expression reflects the underlying biological heterogeneity and necessitates more sophisticated diagnostic tools, possibly integrating advanced neuroimaging, genomics, and proteomics. Bowen highlights ongoing efforts to develop biomarkers capable of distinguishing PD subtypes, which could dramatically improve early diagnosis and monitoring.

Moreover, the review explores environmental and lifestyle factors as critical modulators in the disease’s landscape. Exposure to pesticides, heavy metals, and varying patterns of gut microbiota composition are discussed as influential variables interacting with genetic predispositions, collectively shaping disease onset and progression. Recognizing and quantifying these contributions opens avenues for preventive strategies and public health initiatives aimed at risk reduction—an often overlooked aspect in PD management.

The research also emphasizes the necessity for longitudinal cohort studies that capture the evolving nature of Parkinson’s disease across diverse populations. Current clinical trials typically recruit narrow patient groups, limiting the generalizability of their findings. Bowen calls for inclusive, large-scale initiatives that leverage big data analytics and machine learning to unravel the intricate web of factors defining individual disease trajectories. Such approaches could identify previously unrecognized subtypes and predictive markers crucial to refining both scientific understanding and therapeutic approaches.

Importantly, the heterogeneity of PD challenges the regulatory framework for drug approval as well. Bowen discusses how conventional clinical trial designs, relying on broad patient inclusion criteria and uniform outcome measures, may fail to detect meaningful benefits of targeted therapies. Regulatory bodies may need to adapt by endorsing more flexible trial methodologies, such as adaptive designs or N-of-1 trials, to effectively evaluate interventions tailored to specific patient subsets.

Despite the profound challenges posed by embracing this complexity, the potential rewards are immense. By recognizing Parkinson’s as a constellation of related but distinct disorders, the scientific community can escape the frustrating cycle of repeated clinical trial failures that plague PD drug development. Future breakthrough treatments could then be developed and deployed with greater precision, ultimately transforming the prognosis and quality of life for millions of patients worldwide.

Bowen also addresses the psychological and societal impacts of this new framework. Patients often seek definitive answers and cure promises, but the emerging reality demands nuanced communication and counseling to manage expectations. The medical community’s ability to convey the inherently complex nature of PD while fostering hope for personalized therapies will be pivotal in maintaining patient engagement and adherence.

Furthermore, this intellectual shift has profound implications for research funding and resource allocation. Policymakers and funding agencies might need to recalibrate priorities, supporting multidisciplinary collaborations that integrate genetics, neuroscience, epidemiology, and computational biology. Such synergy is vital to disentangle the multifactorial underpinnings of Parkinson’s heterogeneity and accelerate translational advances.

In addition to genetic and environmental factors, Bowen highlights the enigmatic role of age-related processes in PD pathology. Aging, as the predominant risk factor, interacts with myriad cellular mechanisms—mitochondrial dysfunction, proteostasis impairment, neuroinflammation—additively influencing disease onset and progression. Deciphering how these universal hallmarks of aging interface with genetically and environmentally driven pathways is one of the key frontiers in PD research.

The article underscores innovative techniques being employed to dissect this complexity. Single-cell transcriptomics and proteomics enable unprecedented resolution to characterize neuronal subpopulations affected in PD, while advanced neuroimaging modalities allow dynamic assessment of disease progression in vivo. Bowen presents a compelling case for integrating these cutting-edge tools into clinical research to refine disease classification and inform targeted therapeutic development.

Finally, the conceptual move away from viewing Parkinson’s disease as a monolithic disorder necessitates a cultural transformation within the research and clinical communities. Embracing patient heterogeneity not only optimizes science and medicine but also personalizes care, respecting each individual’s unique disease journey. This comprehensive reappraisal offers a bold yet essential paradigm shift, setting the stage for transformative progress in understanding and ultimately conquering Parkinson’s disease.

Subject of Research: Heterogeneity in Parkinson’s Disease and Implications for Diagnosis and Treatment

Article Title: There is not one Parkinson’s disease, nor is there one cure

Article References:
Bowen, S.J. There is not one Parkinson’s disease, nor is there one cure. npj Parkinsons Dis. 11, 339 (2025). https://doi.org/10.1038/s41531-025-01183-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41531-025-01183-w

Parkinson’s disease and Lewy Body Dementia represent a formidable clinical challenge, characterized by progressive motor dysfunction and cognitive decline, respectively. Although the pathological hallmarks—such as alpha-synuclein aggregation and widespread neuronal loss—are well documented, the molecular triggers remain somewhat elusive. The study’s focus on ATXN2 repeat expansions introduces a fresh genetic paradigm, suggesting that subtle variations within this gene can profoundly influence disease susceptibility and phenotype.

Historically, ATXN2 has been predominantly linked to spinocerebellar ataxia type 2 (SCA2), a disorder caused by trinucleotide repeat expansions leading to neurodegeneration. However, the novel detection of expanded yet interrupted repeats in PD and LBD patients signals an unexpected intersection of pathogenic pathways. The interruptions within the expanded sequences may modulate the toxicity typically associated with pure repeat expansions, hinting at a nuanced form of genetic instability that could affect protein function and neuronal resilience.

To elucidate these findings, the researchers conducted comprehensive genetic screenings across multiple cohorts. Using advanced sequencing technologies, they identified not only the presence of expanded ATXN2 alleles but also complex interruption patterns previously undetected by standard assays. These interrupted expansions appear to escape some of the regulatory mechanisms that usually mitigate repeat-induced cytotoxicity, potentially leading to aberrant ATXN2 protein aggregation and deleterious interactions with RNA-binding proteins.

Intriguingly, the pathogenic potential of these interrupted expansions lies in their capacity to disrupt normal RNA metabolism—a process vital for neuronal health. ATXN2 is known to participate in RNA processing and stress granule formation, both of which are critical for managing cellular stress. Altered repeat expansions may perturb these functions, precipitating deficits in RNA stability and translation that culminate in neuronal dysfunction. This mechanistic insight bridges the gap between genetic mutation and cellular pathology in PD and LBD.

Moreover, the study delineates a correlation between the size and complexity of these expansions with the severity of clinical manifestations. Patients harboring larger or more intricate interruptions exhibited more rapid disease progression and pronounced cognitive decline. This genotype-phenotype relationship underscores the potential utility of ATXN2 repeat profiling not only as a diagnostic biomarker but also as a prognostic tool, guiding personalized therapeutic approaches.

From a therapeutic standpoint, these discoveries open avenues for targeting the pathological consequences of repeat expansions at multiple levels. Approaches could include gene silencing technologies such as antisense oligonucleotides, designed to reduce mutant transcript levels, or small molecules capable of stabilizing RNA-protein interactions disrupted by the ATXN2 mutations. Furthermore, the modulation of stress granule dynamics emerges as a promising strategy to rescue neuronal function compromised by these genetic aberrations.

This paradigm shift in understanding the genetic complexity of PD and LBD emphasizes the necessity of considering interrupted repeats as distinct entities with unique pathogenic properties. Unlike pure expansions that induce toxicity primarily through protein aggregation, interrupted repeats may also instigate RNA toxicity and impaired cellular stress responses. This dual mechanism elevates ATXN2 as a pivotal genetic contributor warranting detailed investigation in neurodegenerative research.

The work also provokes reconsideration of existing genetic testing frameworks. Traditional assays, often calibrated to detect pure trinucleotide expansions, may overlook pathogenic interrupted repeats. Consequently, refining diagnostic methodologies to capture this heterogeneity will be essential for accurate patient stratification and for unlocking the full spectrum of ATXN2-associated pathologies.

By integrating these genetic insights with neuropathological data, the research community gains a more holistic understanding of the molecular events driving PD and LBD. The intersection between retrotransposon-driven genomic instability and RNA processing dysfunction highlighted by ATXN2 abnormalities provides a fertile ground for identifying convergent pathways that unify disparate neurodegenerative conditions.

Additionally, the identification of interrupted ATXN2 expansions compels a reevaluation of genetic risk assessment in family members of affected individuals. The inheritance patterns and penetrance of such interrupted expansions remain to be fully delineated, but preliminary evidence suggests a complex interplay between environmental factors and genetic susceptibility that modulates clinical outcome.

Looking ahead, longitudinal studies tracking the evolution of ATXN2 repeat length and interruption patterns over time will be instrumental. Such studies could reveal dynamic processes of repeat instability that contribute to disease onset and progression, offering critical windows for therapeutic intervention before significant neurodegeneration ensues.

The implications of this research extend beyond molecular biology into clinical practice and public health. Identifying genetic contributors to PD and LBD with such precision facilitates early diagnosis, informs prognosis, and potentially enables pre-symptomatic screening in at-risk populations. This transforms the landscape of neurodegenerative disease management from reactive to proactive.

In sum, the pioneering work by Wang and colleagues heralds a new era in the genetics of neurodegeneration. By peeling back layers of complexity within ATXN2 repeat expansions, they uncover pathogenic nuances that reshape our comprehension of Parkinson’s disease and Lewy Body Dementia. Their findings pave the way for innovative diagnostics and therapeutic paradigms, energizing efforts to quell the growing burden of these devastating disorders.

As research continues to unravel the intricate genetic architecture of neurodegeneration, the role of interrupted repeat expansions likely represents just the tip of the iceberg. The convergence of high-resolution genomic technologies with deep phenotypic profiling promises a future where neurodegenerative diseases are not only better understood but also more effectively treated and, ultimately, prevented.

Subject of Research: Genetic underpinnings and mechanisms of Parkinson’s disease and Lewy Body Dementia focusing on ATXN2 repeat expansions.

Article Title: Identification of expanded and interrupted ATXN2 repeat expansions in Parkinson’s disease and Lewy Body Dementia cohorts.

Article References:
Wang, L., Milton, M., Fearnley, L.G. et al. Identification of expanded and interrupted ATXN2 repeat expansions in Parkinson’s disease and Lewy Body Dementia cohorts. npj Parkinsons Dis. 11, 341 (2025). https://doi.org/10.1038/s41531-025-01188-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41531-025-01188-5